Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
3.390
+0.030 (0.89%)
Apr 9, 2026, 11:07 AM EDT - Market open
Pluri Revenue
Pluri had revenue of $198.00K in the quarter ending December 31, 2025, with 7.03% growth. This brings the company's revenue in the last twelve months to $1.34M, up 97.05% year-over-year. In the fiscal year ending June 30, 2025, Pluri had annual revenue of $1.34M with 309.82% growth.
Revenue (ttm)
$1.34M
Revenue Growth
+97.05%
P/S Ratio
25.81
Revenue / Employee
$9,430
Employees
142
Market Cap
34.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.34M | 1.01M | 309.82% |
| Jun 30, 2024 | 326.00K | 39.00K | 13.59% |
| Jun 30, 2023 | 287.00K | 53.00K | 22.65% |
| Jun 30, 2022 | 234.00K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | 23.00K | -31.00K | -57.41% |
| Jun 30, 2019 | 54.00K | 4.00K | 8.00% |
| Jun 30, 2018 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 8.96M |
| Evaxion | 7.53M |
| Apollomics | 6.93M |
| Dyadic International | 3.09M |
| Longeveron | 1.20M |
| ABVC BioPharma | 797.92K |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
PLUR News
- 3 months ago - Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - GlobeNewsWire
- 11 months ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 1 year ago - Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - GlobeNewsWire
- 1 year ago - Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - GlobeNewsWire
- 1 year ago - Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - GlobeNewsWire
- 1 year ago - Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - GlobeNewsWire
- 1 year ago - Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - GlobeNewsWire
- 1 year ago - Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire